Corvus Pharmaceuticals (CRVS) reported a Q4 loss late Thursday of $0.15 per diluted share, narrowing from a loss of $0.18 a year earlier.

Analysts polled by FactSet expected a loss of $0.13.

As of Dec. 31, 2025, the company had cash, cash equivalents and marketable securities of $56.8 million, expected to fund operations into Q2 of 2028.